Jpmorgan Chase & CO Alzamend Neuro, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$0.19 - $0.52 $9 - $25
49 New
49 $0
Q4 2021

Feb 10, 2022
SELL
$1.9 - $3.08 $1,654 - $2,682
-871 Closed
0 $0
Q3 2021

Nov 12, 2021
BUY
$2.28 - $7.68 $1,985 - $6,689
871 New
871 $3,000

About Alzamend Neuro, Inc.

ALZN Quotes by TradingView
  • Ticker ALZN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 95,481,800
  • Market Cap $115M
  • Description
  • Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...
More about ALZN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email